StreetInsider.com News Articles

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET.

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Tue, 02 Jun 2026 07:00:00 -0400

The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 28 May 2026 16:01:00 -0400

The equity awards were granted in

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics